Saturday, February, 23, 2019 01:26:39

IMV Incorporation, a clinical stage biopharmaceutical company, has reportedly declared the expansion of its clinical program through a Phase 2 basket trial assessing its prime drug, DPX-Survivac, combined with KEYTRUDA (pembrolizumab) and cyclophosphamide, in patients suffering from recurrent or advanced solid tumors.

Frederic Ors, Chief Executive Officer of IMV Incorporation was quoted stating that the company is rather elated to join forces with the American pharmaceutical company Merck across several cancer indications, and is ambitious about inspecting the supplementary benefit of mingling DPX-Survivac & KEYTRUDA®. Ors added that the clinical data presented at the ASCO (American Society of Clinical Oncology) meeting demonstrated the exceptional potential of DPX-Survivac in producing solid tumor regression in ovary cancer for the first time.

Incidentally, the ASCO defines a basket study as a clinical trial that examines the effects of a medicine regimen in various types of tumor whose molecular target is common, irrespective of the disease origination.

For the uninitiated, Phase 2 basket clinical study would assess the efficacy and safety of various immunotherapeutic blend agents in the patients having liver cancer (hepatocellular carcinoma), ovary cancer, non-small cell lung cancer, or bladder cancer besides tumors that are positive for MSI-H (microsatellite instability high) biomarker.

According to the Seeking Alpha, researchers plan to sign-up over two hundred patients across 5 indications at various medical hubs in the United States and Canada. IMV reportedly expects to start clinical trial registration in the fourth quarter of 2018.

This clinical trial is the third trial assessing the combination therapy of pembrolizumab and DPX-Survivac, a low dosage cyclophosphamide in advanced level recurrent cancers.

DPX-Survivac is the chief contender in IMV’s new range of immunotherapies and has shown the potential for cutting-edge targeted, durable, and persistent T-cell activation in fighting cancer, cite sources.

For the record, KEYTRUDA® is a trademarked product of Merck Sharp & Dohme Corp., which is a business subsidiary of Merck & Company Inc., located in Kenilworth, New Jersey, USA.